These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36510622)

  • 21. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
    Brahmi M; Vinceneux A; Cassier PA
    Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognosis of Advanced Tenosynovial Giant Cell Tumor of the Knee Diagnosed During Total Knee Arthroplasty.
    Lei P; Sun R; Liu H; Zhu J; Wen T; Hu Y
    J Arthroplasty; 2017 Jun; 32(6):1850-1855. PubMed ID: 28161138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor.
    Monestime S; Lazaridis D
    Drugs R D; 2020 Sep; 20(3):189-195. PubMed ID: 32617868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenosynovial giant cell tumor-diffuse type, treated with a novel colony-stimulating factor inhibitor, pexidartinib: initial experience with MRI findings in three patients.
    Helming A; Hansford B; Beckett B
    Skeletal Radiol; 2022 May; 51(5):1085-1091. PubMed ID: 34586485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors.
    Lewis JH; Gelderblom H; van de Sande M; Stacchiotti S; Healey JH; Tap WD; Wagner AJ; Pousa AL; Druta M; Lin CC; Baba HA; Choi Y; Wang Q; Shuster DE; Bauer S
    Oncologist; 2021 May; 26(5):e863-e873. PubMed ID: 33289960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial.
    Van De Sande M; Tap WD; Gelhorn HL; Ye X; Speck RM; Palmerini E; Stacchiotti S; Desai J; Wagner AJ; Alcindor T; Ganjoo K; Martín-Broto J; Wang Q; Shuster D; Gelderblom H; Healey JH
    Acta Orthop; 2021 Aug; 92(4):493-499. PubMed ID: 33977825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis.
    Thongchot S; Duangkaew S; Yotchai W; Maungsomboon S; Phimolsarnti R; Asavamongkolkul A; Thuwajit P; Thuwajit C; Chandhanayingyong C
    Hum Cell; 2023 Jan; 36(1):456-467. PubMed ID: 36456782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Updates on the Treatment of Tenosynovial Giant Cell Tumor.
    Chan AS; Katiyar V; Dy P; Singh V
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):307-315. PubMed ID: 37363972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
    Tap WD; Singh AS; Anthony SP; Sterba M; Zhang C; Healey JH; Chmielowski B; Cohn AL; Shapiro GI; Keedy VL; Wainberg ZA; Puzanov I; Cote GM; Wagner AJ; Braiteh F; Sherman E; Hsu HH; Peterfy C; Gelhorn HL; Ye X; Severson P; West BL; Lin PS; Tong-Starksen S
    Clin Cancer Res; 2022 Jan; 28(2):298-307. PubMed ID: 34716196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct extra-articular invasion patterns of diffuse pigmented villonodular synovitis/tenosynovial giant cell tumor in the knee joints.
    Kim DE; Kim JM; Lee BS; Kim NK; Lee SH; Bin SI
    Knee Surg Sports Traumatol Arthrosc; 2018 Nov; 26(11):3508-3514. PubMed ID: 29637236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of tenosynovial giant cell tumour of the foot and ankle.
    Spierenburg G; Lancaster ST; van der Heijden L; Mastboom MJL; Gelderblom H; Pratap S; van de Sande MAJ; Gibbons CLMH
    Bone Joint J; 2021 Apr; 103-B(4):788-794. PubMed ID: 33789469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
    Gelderblom H; de Sande MV
    Future Oncol; 2020 Oct; 16(29):2345-2356. PubMed ID: 32700568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional team.
    McCabe C; Wright H; Polson K; Wagner AJ
    Orphanet J Rare Dis; 2023 Oct; 18(1):313. PubMed ID: 37805596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies.
    Palmerini E; Healey JH; Bernthal NM; Bauer S; Schreuder H; Leithner A; Martin-Broto J; Gouin F; Lopez-Bastida J; Gelderblom H; Staals EL; Mercier F; Laeis P; Ye X; van de Sande M
    Oncologist; 2023 Jun; 28(6):e425-e435. PubMed ID: 36869793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of arthroscopic excision based on the distribution of the tenosynovial giant cell tumor around knee joint.
    Yoo HJ; Nam HS; Park SB; Lee YS
    Knee; 2023 Mar; 41():360-372. PubMed ID: 36848705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment.
    Spierenburg G; Suevos Ballesteros C; Stoel BC; Navas Cañete A; Gelderblom H; van de Sande MAJ; van Langevelde K
    Insights Imaging; 2023 Feb; 14(1):22. PubMed ID: 36725759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of Tenosynovial Giant Cell Tumor of the Foot and Ankle.
    Barnett JR; Rudran B; Khan A; O'Reilly-Harbidge S; Patel S; Malhotra K; Cullen N; Welck M; Aston W
    Foot Ankle Int; 2023 Oct; 44(10):1013-1020. PubMed ID: 37644900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.
    Yin O; Wagner AJ; Kang J; Knebel W; Zahir H; van de Sande M; Tap WD; Gelderblom H; Healey JH; Shuster D; Stacchiotti S
    J Clin Pharmacol; 2021 Apr; 61(4):480-492. PubMed ID: 33043474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total Synovectomy and Bone Grafting/Cementation after Curettage of the Bone Lesion in Diffuse‏ Type ‏of Tenosynovial‏ Giant Cell Tumor‎: A Retrospective Cohort Study.
    Jamshidi K; Sharifi Dalooei SMA; Bagherifard A; Mirzaei A
    Arch Bone Jt Surg; 2023; 11(5):342-347. PubMed ID: 37265527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.